Zatolmilast is under clinical development by Tetra Therapeutics and currently in Phase III for Fragile X Syndrome. According to GlobalData, Phase III drugs for Fragile X Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zatolmilast LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zatolmilast overview

BPN-14770 is under development for the treatment of fragile X syndrome, traumatic brain injury and Alzheimer's disease. The drug candidate is administered through oral route. It acts by targeting enzyme phosphodiesterase 4 (PDE 4D) enzyme.

Tetra Therapeutics overview

Tetra Therapeutics, a subsidiary of Shionogi & Co Ltd, is a biotechnology company that researches and develops pharmaceutical drugs based on phosphodiesterase (PDE) sub-type inhibitors for neuroscience and non-neuroscience disorders. The company’s product pipeline includes BPN14770 PDE4D and pde4b inhibitors for the treatment of fragile x syndrome, Alzheimer’s disease (cognition), Alzheimer’s disease (inflammation), traumatic brain injury, progressive multiple sclerosis (MS) and chronic traumatic encephalopathy (CTE). It uses a structure-guided drug design chemistry approach to discover allosteric inhibitors of phosphodiesterase subtypes such as PDE4B and PDE4D. The company partners with various universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Tetra Therapeutics is headquartered in Kalamazoo, Michigan, the US.

For a complete picture of Zatolmilast’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.